These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35403533)

  • 21. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
    Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Bozzarelli S; Personeni N; Rimassa L
    Expert Opin Investig Drugs; 2022 Apr; 31(4):425-435. PubMed ID: 35152830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highlighting novel targets in immunotherapy for liver cancer.
    Ruff SM; Shannon AH; Beane JD; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2022; 16(11-12):1029-1041. PubMed ID: 36404729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.
    Qin R; Jin T; Xu F
    Front Immunol; 2023; 14():1326097. PubMed ID: 38187399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Brown ZJ; Gregory S; Hewitt DB; Iacono S; Choe J; Labiner HE; Pawlik TM
    Surg Oncol; 2022 Jun; 42():101748. PubMed ID: 35395582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in older patients with hepatocellular carcinoma.
    Lyu N; Yi JZ; Zhao M
    Eur J Cancer; 2022 Feb; 162():76-98. PubMed ID: 34954439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang J; Huang H; Chen R; Lin Y; Ling Q
    Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story.
    Demirtas CO; Gunduz F
    J Gastrointest Cancer; 2021 Dec; 52(4):1217-1222. PubMed ID: 34897577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
    Rizzo A; Dadduzio V; Ricci AD; Massari F; Di Federico A; Gadaleta-Caldarola G; Brandi G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):371-378. PubMed ID: 34167433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment.
    Han R; Li J; Hony J; Xiao Z; Wang J; Yao M; Liang S; Lu L
    Front Immunol; 2023; 14():1052657. PubMed ID: 37006233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in immunotherapy for hepatocellular carcinoma.
    Khan AA; Liu ZK; Xu X
    Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.
    Gabbia D; De Martin S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy and transplantation for hepatocellular carcinoma.
    Tabrizian P; Abdelrahim M; Schwartz M
    J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.
    Cheu JW; Wong CC
    Hepatology; 2021 Oct; 74(4):2264-2276. PubMed ID: 33811765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.